Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | CPA3 | P15088 | 3/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16556234 | 0.87 | CYP1A2 (0.50) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL11514986 | 0.85 | EPHX1 (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL11301059 | 0.83 | CYP1A2 (0.59) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL24513227 | 0.82 | MMP9 (0.50) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL4842827 | 0.81 | ALPI (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL21961161 | 0.81 | CYP1A2 (0.52) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL839467 | 0.81 | ALPI (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL839468 | 0.81 | ALPI (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL1855157 | 0.78 | CYP1A2 (0.53) | CYP1A2ALPIPKMPTGS1XIAP | |
| SCHEMBL9395382 | 0.77 | ALPI (0.49) | CYP1A2ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022224035-A2 | ANTI-GM1 ANTIBODY BINDING COMPOUNDS | POLYNEURON PHARMACEUTICALS AG (CH) | 2022-10-27 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9760030-B2 | Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2017-09-12 | — | — | US | disclosed |
| US-8791268-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8642775-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| US-20110184020-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| EP-2146962-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080262039-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| WO-2008125337-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262039-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | TRPV1, TRPV2, TRPV3 | CYP1A2 1630/4885ALPI 1334/4885PKM 1754/4885 |
| US-20110184020-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions | TRPV1, TRPV2, TRPV3 | CYP1A2 1630/4885ALPI 1334/4885PKM 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.